BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
57.18
-1.26 (-2.16%)
At close: Oct 2, 2026, 4:00 PM EDT
57.34
+0.16 (0.28%)
After-hours: Oct 2, 2026, 7:30 PM EDT
BioMarin Pharmaceutical Employees
BioMarin Pharmaceutical had 3,221 employees as of December 31, 2025. The number of employees increased by 181 or 5.95% compared to the previous year.
Employees
3,221
Change (1Y)
181
Growth (1Y)
5.95%
Revenue / Employee
$1,057,626
Profits / Employee
$22,655
Market Cap
11.07B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 3,221 | 181 | 5.95% |
| Dec 31, 2024 | 3,040 | -361 | -10.61% |
| Dec 31, 2023 | 3,401 | 319 | 10.35% |
| Dec 31, 2022 | 3,082 | 37 | 1.22% |
| Dec 31, 2021 | 3,045 | -14 | -0.46% |
| Dec 31, 2020 | 3,059 | 58 | 1.93% |
| Dec 31, 2019 | 3,001 | 152 | 5.34% |
| Dec 31, 2018 | 2,849 | 268 | 10.38% |
| Dec 31, 2017 | 2,581 | 288 | 12.56% |
| Dec 31, 2016 | 2,293 | 135 | 6.26% |
| Dec 31, 2015 | 2,158 | 477 | 28.38% |
| Dec 31, 2014 | 1,681 | 340 | 25.35% |
| Dec 31, 2013 | 1,341 | 252 | 23.14% |
| Dec 31, 2012 | 1,089 | 87 | 8.68% |
| Dec 31, 2011 | 1,002 | 131 | 15.04% |
| Dec 31, 2010 | 871 | 151 | 20.97% |
| Dec 31, 2009 | 720 | 71 | 10.94% |
| Dec 31, 2008 | 649 | 124 | 23.62% |
| Dec 31, 2007 | 525 | 115 | 28.05% |
| Dec 31, 2006 | 410 | 96 | 30.57% |
| Dec 31, 2005 | 314 | -45 | -12.53% |
| Dec 31, 2004 | 359 | 87 | 31.99% |
| Dec 31, 2003 | 272 | 53 | 24.20% |
| Dec 31, 2002 | 219 | 3 | 1.39% |
| Dec 31, 2001 | 216 | 42 | 24.14% |
| Dec 31, 2000 | 174 | 25 | 16.78% |
| Dec 31, 1999 | 149 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Bio-Techne | 3,000 |
| Axsome Therapeutics | 1,346 |
| BridgeBio Pharma | 1,003 |
| Twist Bioscience | 979 |
| Madrigal Pharmaceuticals | 915 |
| Corcept Therapeutics | 730 |
| ImmunityBio | 691 |
| Halozyme Therapeutics | 423 |
BMRN News
- 1 day ago - BioMarin reports five-year Pompe disease data showing durable motor function - CNBC
- 1 day ago - BioMarin announces five-year Phase 3 data for POMBILITI plus OPFOLDA - TheFly
- 1 day ago - BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress - PRNewsWire
- 3 days ago - Profluent Partners With BioMarin to Design Novel Medicines Using AI - Business Wire
- 18 days ago - BioMarin price target lowered to $97 from $98 at BMO Capital - TheFly
- 18 days ago - BioMarin to discontinue development of Voxzogo for children with Noonan syndrome - TheFly
- 19 days ago - BioMarin Pharmaceutical Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 19 days ago - BioMarin names Robert Plenge, M.D., Ph.D., to board of directors - TheFly